Apnimed, Inc. (NASDAQ:APMD) Short Interest Update

Apnimed, Inc. (NASDAQ:APMD) was the target of a large increase in short interest in the month of August. As of August 14th, there was short interest totaling 407,565 shares, an increase of ∞ from the July 30th total of 0 shares. Based on an average daily volume of 411,465 shares, the days-to-cover ratio is currently 1.0 days. Currently, 1.5% of the shares of the stock are sold short.

Apnimed Stock Performance

Apnimed stock opened at $29.71 on Friday. Apnimed has a fifty-two week low of $16.12 and a fifty-two week high of $35.29.

Insider Buying and Selling at Apnimed

In related news, major shareholder Morningside Venture Investment purchased 312,500 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was acquired at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider directly owned 7,152,713 shares of the company’s stock, valued at $114,443,408. This trade represents a 4.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on APMD. Lifesci Capital assumed coverage on shares of Apnimed in a research report on Tuesday, August 25th. They set an “outperform” rating and a $50.00 price target for the company. Cantor Fitzgerald began coverage on Apnimed in a research note on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price objective for the company. Evercore began coverage on Apnimed in a report on Tuesday. They set an “outperform” rating for the company. Bank of America assumed coverage on Apnimed in a research report on Tuesday, August 25th. They set a “buy” rating and a $41.00 target price on the stock. Finally, Zacks Research raised Apnimed to a “hold” rating in a report on Wednesday. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Apnimed currently has a consensus rating of “Moderate Buy” and a consensus price target of $50.33.

Apnimed Company Profile

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.